Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
复制标题
DOI：
10.1016/s0140-6736(01)06844-1
复制
发表时间：
2001-11-24
期刊：
影响因子：
168.9
通讯作者：
Thorner, M
中科院分区：
文献类型：
--
作者：
van der Lely, AJ;Hutson, RK;Thorner, M
Pegvisomant是一种新的生长激素受体拮抗剂，在治疗长达12周的肢端肥大症患者中改善症状并使胰岛素样生长因子-1 （IGF-1）正常化。我们评估了pegvisomant在160例肢端肥大症患者中平均治疗425天的效果。方法对152例连续18个月每日皮下注射pegvisomant患者的肿瘤体积变化、血清生长激素和IGF-1浓度变化进行评价。安全性分析包括160例患者，其中一些患者每周接受注射，并被排除在疗效分析之外。平均血清IGF-1浓度下降至少50%：治疗6个月、12个月和18个月的患者分别为467杯/升（SE 24）、526杯/升（SE 29）和523杯/升（SE 40）
Background Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulinlike growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days.Methods Treatment efficacy was assessed by measuring changes in tumour volume by magnetic resonance imaging, and serum growth hormone and IGF-1 concentrations in 152 patients who received pegvisomant by daily subcutaneous injection for up to 18 months. The safety analysis included 160 patients some of whom received weekly injections and are excluded from the efficacy analysis.Findings Mean serum IGF-1 concentrations fell by at least 50%: 467 mug/L (SE 24), 526 mug/L (29), and 523 mug/L (40) in patients treated for 6, 12 and 18 months, respectively (p